Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523900 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL8207326 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL27902911 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL5626616 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL576463 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL4529849 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL523899 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL9987097 | 0.90 | KMT2A (0.53) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL14405525 | 0.89 | KMT2A (0.60) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL20306298 | 0.87 | KMT2A (0.48) | KMT2AMAPK1BRD4HSD11B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| CN-104812753-A | Substituted pyridopyrazines as syk inhibitors | HUTCHISON MEDIPHARMA LTD | 2015-07-29 | — | — | CN | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8212072-B2 | Process for the preparation of pregabalin | Divi's Laboratories, Ltd. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212072-B2 | Process for the preparation of pregabalin | Divi's Laboratories, Ltd. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-6642398-B2 | Improving drug qualities such as bioavailability and stability | WARNER-LAMBERT COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192125-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076958-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | KMT2A 823/4885MAPK1 2302/4885BRD4 1303/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | KMT2A 3421/4885MAPK1 3047/4885BRD4 1292/4885 |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPK1 935/4885BRD4 967/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPK1 935/4885BRD4 967/4885 |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | KMT2A 1992/4885MAPK1 4187/4885BRD4 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.